(Q40532403)

English

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.

scientific article published on 11 September 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sebastian Grosicki

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kazimierz Kuliczkowski

2

object named as

Kazimierz Kuliczkowski

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Marinus H J van Oers

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Mario Petrini

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Fritz Offner

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Mark-David Levin

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ira Gupta

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jennifer Phillips

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Vanessa Williams

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Stephanie Manson

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Steen Lisby

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Christian Geisler

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PROLONG study investigators

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

13 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1370-1379

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900143-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00143-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26377300%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40532403&oldid=1496283464"